COVID-19 vaccine update: Novavax vaccine candidate develops high levels of antibodies, shows study

By: |
August 5, 2020 12:29 PM

The company said the number of antibodies found in volunteers who participated in the trials was twice the number of antibodies found in recovered patients from the disease.

Buoyed up by the positive results, the company said that it hoped to commence large scale phase 3 trials of the vaccine by the end of September.Buoyed up by the positive results, the company said that it hoped to commence large scale phase 3 trials of the vaccine by the end of September.

In another positive development in the fight against the coronavirus pandemic, US pharma major Novavax Inc said its COVID-19 vaccine candidate helps develop a substantial amount of antibodies in human bodies against the virus. The positive result from an early-stage clinical trial led to a spurt of up to 10 per cent in the share prices of the pharma company on Tuesday, according to a Reuters report.

The company said the number of antibodies found in volunteers who participated in the trials was twice the number of antibodies found in recovered patients from the disease. It also said that during the trials the volunteers had been administered two small doses of the vaccine. The trials for which the company announced results on Tuesday had begun in the month of May and had enrolled a total of 106 subjects between the age of 18 and 59. The company also said that out of the total participants, eight volunteers also showed up some side effects of the vaccine including headache, fatigue, and muscle pain. However, none of the volunteers needed any medical intervention.

Buoyed up by the positive results, the company said that it hoped to commence large scale phase 3 trials of the vaccine by the end of September. The company also said that subject to positive results from phase 3 trial of the vaccine, the company would be in a position to manufacture anything between 1-2 billion doses of the vaccine in 2021.

As far as taking the necessary regulatory approval for the large scale production of the vaccine, Novavax research chief Gregory Glenn told news agency Reuters that the company would have enough data by the end of December to be able to obtain regulatory approval. The vaccine candidate developed by the company is one of the very few candidates which are being funded by the Operation Warp Speed which is being led by the White House. In July this year, the Donald Trump administration had given $1.6 billion of aid to the company to cover its cost of developing and testing the vaccine in successive trials. The U.S. government is also hoping to obtain more than 100 million doses of the vaccine by January 2021.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19: Pune hospitals struggle with critical patients; doctors, hospital staff crunch likely
2Covid-19 vaccine update: Phase 3 human clinical trial of Oxford vaccine begins in Pune
3India needs to invest Rs 3,000-5,000 crore to create extra manufacturing facilities for COVID-19 vaccine: Zydus Cadila chairman